课题基金 / 基金详情

The Effects of Cytomegalovirus on Organ Transplant Rejection

The Effects of Cytomegalovirus on Organ Transplant Rejection
巨细胞病毒对器官移植排斥的影响
批准号:
9756171
负责人:
Iris Katherine Archer Jones
金额:
$4.5万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-01 至 2021-08-31

项目摘要

项目成果

Iris Katherine Archer Jones的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 心脏移植后慢性排斥反应占患者死亡的30%。标志性的 同种异体实体器官慢性排斥反应(CR)的病变是移植物血管硬化(TVS)。电视加速了 通过移植物部位的炎症和免疫反应。影响炎症免疫的因素很多。 移植物附近的环境会促进慢性排斥反应。其中一个特别令人感兴趣的因素是感染 人巨细胞病毒(HCMV)因为大约75%的人体移植供者/接受者 人群中的人巨细胞病毒呈阳性,开发减轻巨细胞病毒影响的新疗法对 对接受HCMV+供体器官移植的受者进行治疗,以提高移植物存活率并防止CR。然而, 与同种异体TVS和CR的HCMV加速相关的病毒机制尚不清楚。一个 更好地了解这些机制对于提高移植患者的存活率和生活质量至关重要。 病人。 目前的文献表明,增强对病毒和移植物的免疫反应是 领先的候选早期移植物破坏和促进病毒加速同种移植物疾病。寄主 趋化因子通过招募和激活免疫细胞来促进移植物排斥反应,从而提示病毒 编码的趋化因子也可能在促进移植物排斥反应中发挥作用。已知人巨细胞病毒可调节 趋化素轴通过诱导感染后趋化因子的表达,并编码多个趋化因子和 趋化因子受体,包括趋化因子UL128和UL130。然而,这些趋化因子的作用 病毒在病毒致病机制和加速移植排斥反应中所起的作用仍然知之甚少,并成为研究的焦点。 我们的研究成果。我们将使用模拟大鼠心脏移植的体外试验来研究这些关系。 RCMV感染模型和移植前细胞向心脏组织渗透的体内研究, 利用巨细胞病毒UL130、RCMV R131的RCMV同源物。特别是,我们假设病毒- 编码CC-趋化因子R131促进免疫细胞迁移并增加免疫细胞在 体内移植后可能导致TVS炎症和加速的移植 大鼠心脏移植模型。我们的第二个假设是,R131在PEC中与UL130具有类似的作用- 介导进入巨噬细胞和内皮细胞,这可能会促进病毒在 同种异体移植,加重移植物疾病。我们将在具体目标1中通过定义后-来解决这些假设 对R131的翻译修饰以及通过识别RCMV R131中存在的介导迁移的基序 在体外和体内。我们的目标是产生一组缺乏趋化活性的病毒突变体。以特定的目标 2,我们将确定R131在进入巨噬细胞和内皮细胞中的作用以及R131的影响 体内发病机制中的突变。在特定的目标3中,我们将确定R131的突变程度 可能影响同种异体心脏移植物的存活和病理。
英文摘要
Project Summary Transplant chronic rejection accounts for 30% of patient deaths following cardiac transplantation. The hallmark lesion of solid-organ allograft chronic rejection (CR) is transplant vascular sclerosis (TVS). TVS is accelerated by inflammation and immune response at graft sites. Many factors influence the inflammatory immune environment near a graft to promote chronic rejection. One such factor of particular interest is infection with Human Cytomegalovirus (HCMV). Because approximately 75% of the human transplant donor/recipient population is positive for HCMV, the development of novel therapies that mitigate HCMV effects is critical to treat transplant recipients receiving HCMV+ donor organs to increase graft survival and prevent CR. However, the viral mechanisms associated with HCMV-acceleration of allograft TVS and CR are poorly understood. A better understanding of these mechanisms is critical to improving survival and quality of life for transplant patients. Current literature suggests that enhancement of the immune response both against the virus and the graft are leading candidates for early graft destruction and promote viral-acceleration of allograft disease. Host chemokines promote graft rejection by recruiting and activating immune cells, thereby suggesting that virally encoded chemokines may also play a role in promoting graft rejection. HCMV is known to modulate the chemokine axis by inducing chemokine expression following infection, and to encode multiple chemokines and chemokine receptors, including the chemokines UL128 and UL130. However, the role that these chemokines play in viral pathogenesis and acceleration of transplant rejection remains poorly understood, and is the focus of our research. We will investigate these relationships using in vitro assays mimicking a rat cardiac transplant model with RCMV infection and in vivo studies for cellular infiltrate to cardiac tissue prior to transplantation, utilizing the RCMV homologue of HCMV UL130, RCMV R131. In particular, we hypothesize that the virally- encoded CC-chemokine R131 promotes immune cell migration and increases immune cell infiltrate prior to transplantation, which may lead to inflammation and acceleration of TVS following transplantation in an in vivo rat cardiac transplantation model. Our second hypothesis is that R131 has a similar role as UL130 in PEC- mediated entry into macrophages and endothelial cells, which may foster widespread viral dissemination in the allograft, enhancing graft disease. We will address these hypotheses in Specific Aim 1 by defining post- translational modifications to R131 and by identifying motifs present within RCMV R131 that mediate migration in vitro and in vivo. Our goal is to generate a panel of viral mutants that lack chemotactic activity. In Specific Aim 2, we will define the role of R131 in entry into macrophages and endothelial cells and the impacts of R131 mutations in pathogenesis in vivo. In Specific Aim 3, we will determine the degree to which mutations in R131 may affect survival of and pathology in cardiac allografts.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Effects of Cytomegalovirus on Organ Transplant Rejection
  • 批准号:
    10020165
  • 项目类别:
  • 资助金额:
    $2.65万
  • 财政年份:
    2019
  • 负责人:
    Iris Katherine Archer Jones
  • 依托单位:
海外基金